New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2013
07:47 EDTBIIBBiogen price target raised to $203 from $187 at Brean Capital
Brean Capital raised its price target on Biogen following the FDA approval of Tecfidera labeling. The approval removes an overhang and suggests consensus revenue guidance of $330M is achievable. Shares are Buy rated.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
07:08 EDTBIIBBiogen reports Q3 TECFIDERA revenues $787M
Subscribe for More Information
07:03 EDTBIIBBiogen raises FY14 adjusted EPS view to $13.45-$13.55, consensus $13.10
Still sees revenue growth 38%-41% vs. 2013, consensus $9.69B. $&D expense is expected to be approximately 20% to 21% of total revenue.
07:02 EDTBIIBBiogen reports Q3 adjusted EPS $3.80, consensus $3.46
Reports Q3 revenue $2.51B, consensus $2.48B.
October 21, 2014
15:35 EDTBIIBNotable companies reporting before tomorrow's open
Subscribe for More Information
06:54 EDTBIIBBiogen October weekly volatility elevated into Q3 and outlook
Subscribe for More Information
October 20, 2014
07:32 EDTBIIBCubist names Perez CEO to succeed Bonney
Subscribe for More Information
October 14, 2014
11:23 EDTBIIBBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use